Board Change • May 21
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CFO & Executive Director Alastair Judge was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Anuncio • Nov 21
Johnson Matthey Plc to Report Fiscal Year 2026 Results on May 28, 2026 Johnson Matthey Plc announced that they will report fiscal year 2026 results on May 28, 2026 Anuncio • Jul 18
Johnson Matthey Plc Approves Final Dividend Johnson Matthey Plc announced at annual general meeting held on July 17, 2025, the shareholders approved final dividend of 55.00 pence per share. Anuncio • Jul 17
Johnson Matthey plc Announces Board Changes Johnson Matthey announced the appointment of Andrew Cosslett as Non-Executive Chair of the Board, with effect from the conclusion of Annual General Meeting. Andrew will succeed Patrick Thomas who will step down from the Board at the end of the AGM. Andrew is an experienced Chair with a strong track record in leading significant transformational and cultural change and delivering long-term shareholder value. He has held a number of senior executive and non-executive roles across a range of sectors, including consumer goods, hospitality and media. His extensive boardroom experience and commercial insight will support the Company's strategy as it becomes a highly focused and leaner business, driving sustainable cash generation. Andrew is currently Chair of ITV plc and previously served as Chair of Kingfisher plc and the Rugby Football Union (RFU). He is the former Chief Executive Officer of both InterContinental Hotels Group PLC and Fitness First. Andrew received a CBE for services to the RFU in the 2022 New Year's Honours List. Upon joining the Board, Andrew will also become a member and Chair of the Nomination Committee and member of the Societal Value Committee. Andrew has been a director of ITV plc since June 2022. From June 2017 until June 2024, Andrew was a director of Kingfisher plc. Anuncio • Jan 27
Johnson Matthey plc Announces Establishment of Investment Committee Johnson Matthey Plc announced the establishment of an Investment Committee of the Board. The Committee, established on 24th January 2025, will reinforce the Company's investment strategies and capital allocation. The Board recognises the need for the Company to remain agile in uncertain markets and adapt its investment strategy and capital allocation as needed, alongside identifying initiatives to accelerate and deliver cash generation and enhanced returns on capital. The Committee will provide additional oversight to these areas in line with the Company's commitment to delivering sustainable shareholder value. Specific responsibilities of the Committee will include review and endorsement of i) investment and capital allocation strategy, ii) major capital projects and, iii) M&A activity. In discharging these duties, the Committee will give consideration to leading market indicators, execution risk, and levels of return and cash generation for shareholders. The Committee will be chaired by Barbara Jeremiah, Senior Independent Director and will initially consist of the following additional members: Liam Condon- Chief Executive, Sinead Lynch-Independent Non-Executive Director, Stephen Oxley-Chief Financial Officer, and Doug Webb-Independent Non-Executive Director. Anuncio • Sep 23
Johnson Matthey Plc(LSE:JMAT) dropped from FTSE All-World Index (USD) Johnson Matthey Plc(LSE:JMAT) dropped from FTSE All-World Index (USD) Anuncio • Sep 09
Johnson Matthey plc Announces Board and Committee Changes Johnson Matthey Plc announced the appointment of Sinead Lynch as an independent Non-Executive Director with effect from 1st January 2025. Sinead will also become a member of the Remuneration, Nomination and Societal Value Committees. Sinead brings a deep understanding of low carbon energy and sustainability, having spent 30 years in the energy sector at Royal Dutch Shell ("Shell") and BG Group ("BG"), including the last 10 years in an executive capacity. Most recently, she led Shell's Low Carbon Fuels business, developing technologies and investing in projects to produce sustainable renewable fuels at scale. Prior to this, Sinead was the UK Country Chair at Shell and led the Safety and Sustainability division of BG before its acquisition by Shell. She was also co-chair of the UK Hydrogen Advisory Council from 1st July 2020 until 1st August 2021. Following a seven-year tenure, Jane Griffiths has taken the decision to step down as Chair of the Societal Value Committee and from the Board on 31st December 2024. Rita Forst will succeed Jane as Chair of the Societal Value Committee from 1st January 2025. Anuncio • Jul 19
Johnson Matthey Plc Declares a Final Dividend Johnson Matthey Plc at its Annual General Meeting held on 18 July 2024 declared a final dividend of 55.00 pence per ordinary share. Anuncio • Jul 04
Johnson Matthey Plc (LSE:JMAT) announces an Equity Buyback for £250 million worth of its shares. Johnson Matthey Plc (LSE:JMAT) announces a share repurchase program. Under the program, the company will repurchase up to £250 million worth of its shares. The sole purpose of the program is to reduce the share capital of the company. All shares repurchased will be cancelled. The program will commence immediately and end no later than November 4, 2024. Anuncio • Jul 02
Montagu Private Equity LLP acquired Medical Device Components business from Johnson Matthey Plc (LSE:JMAT). Montagu Private Equity LLP agreed to acquire Medical Device Components business from Johnson Matthey Plc (LSE:JMAT) for £550 million on March 20, 2024. The consideration will be paid on a cash free debt free basis. The sale proceeds will be payable in cash at completion. The gross assets that are the subject of this transaction amounted to £60 million as at September 30, 2023. Transaction is subject to regulatory approval. The transaction is expected to complete around Q3 2024. Goldman Sachs International acted as exclusive financial adviser to Johnson Matthey. Raymond James & Associates, Inc. acted as financial advisor, Kirkland & Ellis LLP as legal advisor, and PwC acted as accounting due diligence transaction advisor to Montagu.
Montagu Private Equity LLP completed the acquisition of Medical Device Components business from Johnson Matthey Plc (LSE:JMAT) on July 1, 2024. Anuncio • Jul 01
Johnson Matthey plc Announces Stephen Oxley, Chief Financial Officer to Step Down Johnson Matthey Plc announced that Stephen Oxley, Chief Financial Officer, has advised the board that he has decided to leave the Company in 2025 to pursue another opportunity. Stephen will continue with his existing responsibilities and will step down from the board by no later than 31st March 2025. The board has commenced a process to identify a successor to Stephen and an appointment will be announced in due course. Declared Dividend • May 27
Final dividend of UK£0.55 announced Dividend of UK£0.55 is the same as last year. Ex-date: 6th June 2024 Payment date: 6th August 2024 Dividend yield will be 4.3%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is not covered by earnings (131% earnings payout ratio). However, it is covered by cash flows (63% cash payout ratio). The dividend has increased by an average of 2.5% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 45% to bring the payout ratio under control. EPS is expected to grow by 156% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Reported Earnings • May 25
Full year 2024 earnings released: EPS: UK£0.59 (vs UK£1.44 in FY 2023) Full year 2024 results: EPS: UK£0.59 (down from UK£1.44 in FY 2023). Revenue: UK£12.8b (down 14% from FY 2023). Net income: UK£108.0m (down 59% from FY 2023). Profit margin: 0.8% (down from 1.8% in FY 2023). Revenue is expected to fall by 60% p.a. on average during the next 3 years compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Anuncio • May 24
Johnson Matthey Plc to Report First Half, 2025 Results on Nov 27, 2024 Johnson Matthey Plc announced that they will report first half, 2025 results on Nov 27, 2024 Reported Earnings • Nov 25
First half 2024 earnings released: EPS: UK£0.34 (vs UK£0.82 in 1H 2023) First half 2024 results: EPS: UK£0.34 (down from UK£0.82 in 1H 2023). Revenue: UK£6.53b (down 11% from 1H 2023). Net income: UK£63.0m (down 58% from 1H 2023). Profit margin: 1.0% (down from 2.0% in 1H 2023). Revenue is expected to fall by 35% p.a. on average during the next 3 years compared to a 4.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. New Risk • Nov 24
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 42% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (42% net debt to equity). Dividend is not well covered by cash flows (313% cash payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.3% net profit margin). New Risk • Oct 06
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Anuncio • Sep 18
Johnson Matthey Plc(LSE:JMAT) dropped from FTSE 100 Index Johnson Matthey Plc(LSE:JMAT) dropped from FTSE 100 Index Anuncio • Jul 23
Johnson Matthey plc Approves Final Dividend Johnson Matthey Plc approved to declare a final dividend of 55.00 pence per ordinary share. Anuncio • Jun 13
Johnson Matthey Plc to Report First Half, 2024 Results on Nov 23, 2023 Johnson Matthey Plc announced that they will report first half, 2024 results on Nov 23, 2023 Upcoming Dividend • Jun 02
Upcoming dividend of UK£0.55 per share at 4.4% yield Eligible shareholders must have bought the stock before 08 June 2023. Payment date: 01 August 2023. Payout ratio is a comfortable 53% but the company is not cash flow positive. Trailing yield: 4.4%. Lower than top quartile of British dividend payers (5.9%). Higher than average of industry peers (2.6%). Reported Earnings • May 26
Full year 2023 earnings released: EPS: UK£1.44 (vs UK£0.61 in FY 2022) Full year 2023 results: EPS: UK£1.44 (up from UK£0.61 in FY 2022). Revenue: UK£14.9b (down 6.8% from FY 2022). Net income: UK£264.0m (up 128% from FY 2022). Profit margin: 1.8% (up from 0.7% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 48% p.a. on average during the next 3 years, while revenues in the Chemicals industry in the United Kingdom are expected to grow by 2.2%. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Anuncio • May 05
Souter Investments Limited and Sullivan Street Partners Ltd agreed to acquire Diagnostic Services Business of Johnson Matthey Plc for £55 million. Souter Investments Limited and Sullivan Street Partners Ltd agreed to acquire Diagnostic Services Business of Johnson Matthey Plc for £55 million on May 3, 2023. The transaction is subject to customary completion conditions. The transaction is expected to complete in the third quarter of calendar 2023. Paul Mudie of Slaughter and May acted as legal advisor to Johnson Matthey Plc. Upcoming Dividend • Dec 01
Upcoming dividend of UK£0.22 per share Eligible shareholders must have bought the stock before 08 December 2022. Payment date: 01 February 2023. Payout ratio is a comfortable 36% but the company is not cash flow positive. Trailing yield: 3.7%. Lower than top quartile of British dividend payers (5.7%). Higher than average of industry peers (2.9%). Reported Earnings • Nov 24
First half 2023 earnings released: EPS: UK£0.82 (vs UK£0.14 loss in 1H 2022) First half 2023 results: EPS: UK£0.82 (up from UK£0.14 loss in 1H 2022). Revenue: UK£7.33b (down 15% from 1H 2022). Net income: UK£150.0m (up UK£178.0m from 1H 2022). Profit margin: 2.0% (up from net loss in 1H 2022). The move to profitability was driven by lower expenses. Revenue is expected to fall by 14% p.a. on average during the next 3 years compared to a 9.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Jun 02
Upcoming dividend of UK£0.55 per share Eligible shareholders must have bought the stock before 09 June 2022. Payment date: 02 August 2022. The company is paying out more than 100% of its profits and is paying out 91% of its cash flow. Trailing yield: 3.7%. Lower than top quartile of British dividend payers (4.9%). Higher than average of industry peers (2.8%). Reported Earnings • May 27
Full year 2022 earnings released: EPS: UK£0.60 (vs UK£1.06 in FY 2021) Full year 2022 results: EPS: UK£0.60 (down from UK£1.06 in FY 2021). Revenue: UK£16.0b (up 2.2% from FY 2021). Net income: UK£116.0m (down 43% from FY 2021). Profit margin: 0.7% (down from 1.3% in FY 2021). Over the next year, revenue is expected to shrink by 75% compared to a 18% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improved over the past week After last week's 23% share price gain to UK£22.44, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 21x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£29.26 per share. Buying Opportunity • Feb 25
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be UK£22.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% per annum over the last 3 years. Earnings per share has declined by 36% per annum over the last 3 years. Buying Opportunity • Feb 25
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be UK£22.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% per annum over the last 3 years. Earnings per share has declined by 36% per annum over the last 3 years. Buying Opportunity • Feb 09
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 22%. The fair value is estimated to be UK£22.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% per annum over the last 3 years. Earnings per share has declined by 36% per annum over the last 3 years. Recent Insider Transactions • Jan 07
Independent Non-Executive Director recently bought UK£52k worth of stock On the 4th of January, Doug Webb bought around 3k shares on-market at roughly UK£20.73 per share. In the last 3 months, there was an even bigger purchase from another insider worth UK£97k. Insiders have collectively bought UK£240k more in shares than they have sold in the last 12 months. Recent Insider Transactions • Dec 25
CEO & Executive Director recently bought UK£97k worth of stock On the 22nd of December, Robert MacLeod bought around 5k shares on-market at roughly UK£19.46 per share. This was the largest purchase by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months. Reported Earnings • Nov 27
First half 2022 earnings: EPS in line with expectations, revenues disappoint First half 2022 results: UK£0.14 loss per share (down from UK£0.13 profit in 1H 2021). Revenue: UK£8.59b (up 23% from 1H 2021). Net loss: UK£28.0m (down 217% from profit in 1H 2021). Revenue missed analyst estimates by 4.3%. Over the next year, revenue is expected to shrink by 75% compared to a 1.3% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment deteriorated over the past week After last week's 18% share price decline to UK£22.52, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 24x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£36.18 per share. Board Change • Nov 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Rita Forst was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jun 17
Full year 2021 earnings released: EPS UK£1.06 (vs UK£1.33 in FY 2020) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: UK£15.7b (up 7.5% from FY 2020). Net income: UK£205.0m (down 20% from FY 2020). Profit margin: 1.3% (down from 1.7% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Jun 03
Upcoming dividend of UK£0.50 per share Eligible shareholders must have bought the stock before 10 June 2021. Payment date: 03 August 2021. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (4.0%). Higher than average of industry peers (1.6%). Reported Earnings • May 28
Full year 2021 earnings released: EPS UK£1.06 (vs UK£1.33 in FY 2020) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: UK£15.7b (up 7.5% from FY 2020). Net income: UK£205.0m (down 20% from FY 2020). Profit margin: 1.3% (down from 1.7% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 16
New 90-day high: UK£30.83 The company is up 21% from its price of UK£25.43 on 18 November 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£30.27 per share. Executive Departure • Feb 06
Independent Non-Executive Director has left the company On the 26th of January, Christopher Mottershead's tenure as Independent Non-Executive Director ended after 6.0 years in the role. As of September 2020, Christopher personally held 2.81k shares (UK£66k worth at the time). A total of 6 executives have left over the last 12 months. Is New 90 Day High Low • Jan 27
New 90-day high: UK£30.00 The company is up 37% from its price of UK£21.97 on 28 October 2020. The British market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£24.56 per share. Is New 90 Day High Low • Jan 06
New 90-day high: UK£27.03 The company is up 11% from its price of UK£24.39 on 08 October 2020. The British market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. Its price trend is also similar to the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£25.96 per share.